DE69232309T2 - Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen - Google Patents

Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen

Info

Publication number
DE69232309T2
DE69232309T2 DE69232309T DE69232309T DE69232309T2 DE 69232309 T2 DE69232309 T2 DE 69232309T2 DE 69232309 T DE69232309 T DE 69232309T DE 69232309 T DE69232309 T DE 69232309T DE 69232309 T2 DE69232309 T2 DE 69232309T2
Authority
DE
Germany
Prior art keywords
beta
tgf
pct
molecules
binding molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232309T
Other languages
English (en)
Other versions
DE69232309T4 (de
DE69232309D1 (de
Inventor
Hidenori Ichijo
Kohei Miyazono
Lars Roennstrand
Ulf Hellman
Christer Wernstedt
Carl-Henrik Heldin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research New York
Application granted granted Critical
Publication of DE69232309T2 publication Critical patent/DE69232309T2/de
Publication of DE69232309T4 publication Critical patent/DE69232309T4/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69232309T 1991-06-18 1992-06-18 Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen Expired - Lifetime DE69232309T4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/717,316 US5229495A (en) 1991-06-18 1991-06-18 Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
PCT/US1992/005199 WO1992022319A1 (en) 1991-06-18 1992-06-18 SUBSTANTIALLY PURE RECEPTOR LIKE TGF-β1 BINDING MOLECULES AND USES THEREOF

Publications (2)

Publication Number Publication Date
DE69232309T2 true DE69232309T2 (de) 2002-08-14
DE69232309T4 DE69232309T4 (de) 2003-02-20

Family

ID=24881526

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69232309T Expired - Lifetime DE69232309T4 (de) 1991-06-18 1992-06-18 Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
DE69232309A Expired - Fee Related DE69232309D1 (de) 1991-06-18 1992-06-18 Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69232309A Expired - Fee Related DE69232309D1 (de) 1991-06-18 1992-06-18 Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen

Country Status (10)

Country Link
US (3) US5229495A (de)
EP (1) EP0590071B1 (de)
JP (1) JPH06508519A (de)
AT (1) ATE211171T1 (de)
AU (1) AU665561B2 (de)
CA (1) CA2111853C (de)
DE (2) DE69232309T4 (de)
DK (1) DK0590071T3 (de)
ES (1) ES2165843T3 (de)
WO (1) WO1992022319A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5705609A (en) * 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5177197A (en) * 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5229495A (en) * 1991-06-18 1993-07-20 Ludwig Institute For Cancer Research Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6008011A (en) * 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
US20080070842A1 (en) * 1991-11-04 2008-03-20 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
ATE238417T1 (de) * 1991-11-04 2003-05-15 Inst Genetics Llc Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US5847007A (en) * 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1996040098A2 (en) 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
ES2255059T3 (es) * 1993-12-07 2006-06-16 Genetics Institute, Llc Bmp-12, bmp-13 y composiciones suyas inductoras de tendon.
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
AU774427B2 (en) 1999-10-15 2004-06-24 Fidia Advanced Biopolymers S.R.L. Formulations of hyaluronic acid for delivery of osteogenic proteins
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
US7226587B2 (en) * 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク X線回折による応力測定法
UA88275C2 (ru) * 2003-09-12 2009-10-12 Уайет Композиция, которая включает остеогенный белок и фосфат кальция, которая имеет форму твердого штифта, пригодного для внутрикостной инъекции, способ ее получения и применения
US20060239951A1 (en) * 2005-03-30 2006-10-26 Alexandre Valentin Methods for stimulating hair growth by administering BMPs
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725798B2 (ja) * 1986-12-15 1995-03-22 東燃料株式会社 TGF−β制御糖タンパク質
CA2002011A1 (en) * 1988-11-14 1990-05-14 Anthony F. Purchio Normal human growth regulatory receptor for tgf-beta
US5177197A (en) * 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
ATE253589T1 (de) * 1990-09-26 2003-11-15 Inst Genetics Llc Bmp-5-derivate
US5229495A (en) * 1991-06-18 1993-07-20 Ludwig Institute For Cancer Research Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US5280109A (en) * 1992-01-27 1994-01-18 Ludwig Institute For Cancer Research Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2

Also Published As

Publication number Publication date
DE69232309T4 (de) 2003-02-20
AU665561B2 (en) 1996-01-11
DK0590071T3 (da) 2002-04-15
EP0590071B1 (de) 2001-12-19
ATE211171T1 (de) 2002-01-15
WO1992022319A1 (en) 1992-12-23
CA2111853A1 (en) 1992-12-23
US5229495A (en) 1993-07-20
AU2261892A (en) 1993-01-12
ES2165843T3 (es) 2002-04-01
DE69232309D1 (de) 2002-01-31
EP0590071A1 (de) 1994-04-06
JPH06508519A (ja) 1994-09-29
EP0590071A4 (en) 1997-01-29
US5578703A (en) 1996-11-26
CA2111853C (en) 2002-09-17
US5731200A (en) 1998-03-24

Similar Documents

Publication Publication Date Title
DE69232309D1 (de) Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
CY1112101T1 (el) Νευροτροφικοι παραγοντες
DE69629181D1 (de) Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen
DK0713495T3 (da) Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner
DE69638162D1 (de) Bindegewebs wachstumsfaktor (ctgf)
ATE151113T1 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DE69020007D1 (de) Vernetzte Antikörper und Verfahren zu ihrer Herstellung.
ATE89566T1 (de) Molekuele mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum- produzierten proteins in hepatozyten und zusammensetzungen davon.
EP1985705A3 (de) Nukleotidsequenzen von Pestivirus-Stämmen, Polypeptide zur Kodierung dieser Sequenzen und deren Verwendung zur Diagnose und Verhinderung von Pestivirus-Infektionen
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
DE69020182T2 (de) Vernetzte Antikörper und Verfahren zu ihrer Herstellung.
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
DK0486572T3 (da) Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
ATE305037T1 (de) Peptide, die fähig sind die sh3-domäne des gap- proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung
CA2273855A1 (en) Novel feline fc epsilon receptor alpha chain nucleic acid molecules, proteins and uses thereof
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
DE59003113D1 (de) Bindemittelkombinationen, ein Verfahren zu ihrer Herstellung und ihre Verwendung.
FI100556B (fi) Menetelmä anti-DNA-vasta-aineiden toteamiseksi, diagnostinen menetelmä , reagenssipakkaus ja lääkeaine autoimmuunisairauksia varten
ATE281519T1 (de) Klonierung und rekombinante herstellung des crf- rezeptors (crf=corticotropin ausloese faktor)
PT524421E (pt) Herpesvirus humano tipo 6 proteina p 100, sequencias de adn correspondentes, preparacao e utilizacao
SE9604439D0 (sv) New receptor
DE60023149D1 (de) Neue inulin-fraktionen, verfahren zu deren herstellung und ihre verwendung